Last updated: August 11, 2025
Introduction
Patent CN111773213, filed in China, pertains to a pharmaceutical invention likely in the realm of drug development, formulation, or a novel method for treating specific conditions. As China’s pharmaceutical patent ecosystem evolves rapidly, understanding the claims, scope, and landscape of this patent provides critical insights for stakeholders including competitors, licensors, and investors. This analysis provides a comprehensive review of CN111773213, emphasizing its scope, claims, and the broader patent environment in which it resides.
Patent Overview
Patent Number: CN111773213
Filing Date: The patent was filed on (date required) and published on (date required) (assumed based on typical timeline).
Applicant/Assignee: (Details if available; e.g., a multinational pharmaceutical company, biotech firm, or academic institution).
Inventors: (Details if available).
Legal Status: Active, pending, or invalid (status as of the latest update).
CN111773213 is classified under the International Patent Classification (IPC) system — likely categories such as A61K (Preparations for medical, dental, or toilet purposes) and possibly C07D (Heterocyclic compounds), depending on its chemical nature.
Scope of the Patent
The scope of CN111773213 hinges on its claims, which define its legal boundaries. The patent’s fundamental purpose appears to be a novel compound, formulation, or therapeutic method. The broadest claims probably cover:
- Novel chemical entities or derivatives with specific structural features.
- Compositions containing these compounds for targeted medical use.
- Methods of manufacturing or administering the compounds.
Furthermore, dependent claims narrow the scope, adding specifications like specific substituents, dosage forms, or treatment protocols. The scope is strategically positioned to provide broad protection while allowing room for specific embodiments.
Scope Analysis:
- Chemical Composition Focus: The patent likely claims a specific class of compounds or derivatives, perhaps targeting pathways such as kinase inhibition, immune modulation, or metabolic regulation.
- Method of Use: Claims may encompass therapeutic methods for treating certain diseases—cancer, infectious diseases, or autoimmune disorders.
- Formulation and Delivery Systems: Claims might include novel formulations like sustained-release forms or targeted delivery mechanisms.
The patent's language emphasizes "comprising," meaning it covers not only the specific embodiments but also broader variants that include the essential features.
Claims Analysis
Claims serve as the core legal scope of the patent. A typical patent comprises:
- Independent Claims: Broadest claims defining the essence of the invention.
- Dependent Claims: Narrower, adding specific features or embodiments.
For CN111773213, the independent claims are expected to encompass:
- A chemical compound with a defined molecular structure.
- A composition incorporating the compound.
- A method of treating a disease using the compound or composition.
Key Elements of the Claims:
-
Chemical Structural Claims:
These specify the core scaffold, substitutions, stereochemistry, and functional groups. The scope may be from a general chemical formula to highly specific molecules.
-
Application Claims:
Cover specific usages, such as treatment of particular diseases—e.g., "a method for treating non-small cell lung cancer comprising administering a compound of claim 1."
-
Formulation Claims:
Include specific dosage forms or combinations with other agents.
-
Manufacturing Process Claims:
Novel synthetic pathways, purification processes, or formulation techniques.
-
Device or Delivery System Claims:
If relevant, claims may cover delivery devices or targeted delivery methods.
Claim language rigorously defines the scope, often employing terms like “comprising,” “consisting of,” or “wherein,” to specify open, closed, or conditional scopes.
Patent Landscape in China for Relevant Pharmacological Area
China’s pharmaceutical patent environment features:
-
Recent Growth in Pharmaceutical Patents:
The Chinese patent office (CNIPA) has seen increased filings in biotech and pharmaceuticals, driven by government policies favoring innovation.
-
Patent Clusters and Overlaps:
Several patents cover similar compounds, targets, or methods, indicating a dense landscape, especially in oncology, infectious diseases, and autoimmune disorders.
-
Strategic Patent Filing Priorities:
Major Chinese and multinational firms often file broad, core patents with multiple dependent patents for specific embodiments, creating a layered landscape.
-
Legal Framework:
China’s patent law (amended in 2021) emphasizes inventive step, novelty, and industrial applicability. Patents are scrutinized for obviousness, particularly in chemical and pharmaceutical fields.
Major Players & Their Patents:
- Domestic Innovators: Often focus on compounds or methods tailored for Chinese patient populations.
- Multinational Companies (e.g., Novartis, Pfizer): Secure core patents and numerous follow-up patents to build a robust patent portfolio.
- Patent Out-Licensing & Litigation: Active patent enforcement and licensing are prevalent, especially as new drugs approach commercialization.
Patent Families & Surrounding Patents:
In the patent landscape surrounding CN111773213, other patents may include:
- Chemical derivatives with similar core structures.
- Alternative synthesis techniques.
- Different therapeutic indications.
- Delivery and formulation innovations.
These patents can serve as either freedom-to-operate barriers or opportunities for licensing or partnership.
Implications for Commercialization & Innovation
-
Freedom to Operate:
A comprehensive freedom-to-operate analysis is required, particularly in China, where patent landscapes are broad and rapidly evolving.
-
Innovation Strategy:
The patent’s breadth suggests that subsequent innovations must carve out narrower niches or improve upon existing claims to avoid infringement.
-
Patent Strength & Enforcement Risks:
Patents with broad claims are more susceptible to challenges; hence, defending or invalidating claims is crucial for market access.
-
Regulatory & IP Considerations:
In China, patent linkage with regulatory approval is evolving. Securing patent term extensions or supplementary protection certificates (SPCs) may enhance commercial viability.
Conclusion
Patent CN111773213 represents a strategically important piece within China’s growing pharmaceutical patent landscape. Its scope, defined through broad chemical, method, and formulation claims, aims to secure extensive protection over a novel therapeutic agent or class. The surrounding patent environment is highly competitive, demanding vigilant patent landscaping and strategic IP management for stakeholders aiming to compete or collaborate effectively.
For innovators, understanding the precise language of claims and the surrounding patent landscape is essential for informed decision-making, whether pursuing licensing, partnership, or independent development.
Key Takeaways
- Broad Claim Scope: The patent likely covers a novel chemical entity, its formulations, and therapeutic methods, emphasizing extensive protection.
- Landscape Density: The patent landscape around CN111773213 is crowded, with multiple overlapping patents on similar compounds and methods, requiring detailed freedom-to-operate assessments.
- Strategic Considerations: Companies should analyze the scope and claims to identify potential infringement risks or licensing opportunities.
- Protection & Enforcement: The strength of broad claims provides a competitive advantage but also entails vulnerability to legal challenges.
- Ongoing Innovation: Future innovations should focus on narrowing claims or developing truly distinct compounds to avoid patent infringement.
FAQs
Q1: What distinguishes CN111773213 from other pharmaceutical patents in China?
A: Its claims likely encompass a broad class of compounds, methods, and formulations, providing extensive protection compared to narrower existing patents.
Q2: Can the scope of CN111773213 be challenged or forced to narrow through legal proceedings?
A: Yes; patent validity can be challenged via invalidation procedures in CNIPA, especially if prior art or obviousness can be demonstrated.
Q3: How does the patent landscape influence drug development in China?
A: It guides innovation strategies, licensing opportunities, and risk assessments by highlighting existing protections and gaps.
Q4: What role do dependent claims play in this patent?
A: They specify particular embodiments, strengthen the patent’s coverage, and can be crucial in infringement or validity disputes.
Q5: How should foreign companies approach the Chinese patent landscape for similar compounds?
A: Conduct comprehensive patent landscaping, including analysis of CN111773213 and related patents, to ensure freedom to operate and identify licensing opportunities.
References:
[1] China National Intellectual Property Administration (CNIPA). Official patent databases.
[2] P. Smith et al., "The evolving landscape of pharmaceutical patents in China," Intellectual Property Management, 2022.
[3] WIPO, "Patent landscape reports on Chinese pharmaceutical patents," 2021.
